Media relations
HOME>Company>Media relations
36 Pharmaceutical Companies to Renew Their Certification as Innovative Pharmaceutical Company
2017.01.24 | 김미희
5 Pharmaceutical Companies Including Kwang Dong Pharm., Donghwa Pharm., Il-dong Pharm., SK Bio-Pharm., and Binex Fail to Renew Their Certification
The Ministry of Health and Welfare announced on the 26th that it had reviewed the 41 pharmaceutical companies, which were designated as innovative pharmaceutical companies in 2012 and recently applied to renew their certification, and 36 of them successfully renewed their status. The 31 companies include 30 general pharmaceutical companies, 5 bio ventures, and 5 foreign pharmaceutical companies.
The specific list of the 36 companies is as follows: Green Cross Corp. [006280], Daewoong Pharm. [069620], Daewon Pharm. [003220], Dongkook Pharm. [086450], Boryung Pharm. [003850], Bukwang Pharm. [003000], Samjin Pharm. [005500], Celltrion Pharm. [068270], Shinpoong Pharm. [019170], Ahngook Pharm. [001540], Yuhan Corp. [000100], Ilyang Pharm. [007570], Chong Kun Dang Pharm[185750], Taejoon Pharm., Korea United Pharm, Handok Pharm [002390], Hanlim Pharm., Hanmi Pharm. [128940], CJ HealthCare, JW THERIAC Pharmaceutical Corp. [001060], LG Life Sciences [068870], SK Chemicals [006120], Kuhnil Pharm., Daehwa Pharm. [067080], Samyang BioPharm., ST Pharm, ISU ABXIS [086890], Kolmar Korea [161890], HanAll BIOPharma [009420], Hyundai Pharm. [004310], Medytox [086900], ViroMed [084990], BC World Pharm [200780], Bioneer [064550], CrystalGenomics, and Korea Otsuka Pham.
The 5 innovative pharmaceutical companies that failed to renew their status this time include Kwang Dong Pharm., Donghwa Pharm., Il-dong Pharm., SK Bio-Pharm., and Binex.
The Ministry of Health and Welfare explained that the sales of the innovative pharmaceutical companies’ every medical product increased and their investments went up as well after they obtained certification (2012-2014) than before (2009-2011). Innovative pharmaceutical companies are the companies that are certified to have excellent and sufficient ability to develop new drugs and enter overseas markets, based on Special Act on Fostering and Support of Pharmaceutical Industry.
The Ministry of Health and Welfare has been enforcing the innovative pharmaceutical certification system since 2012 to promote the growth and international competitiveness of the pharmaceutical industry. The ministry selected a total of 46 innovative pharmaceutical companies through certification in 2012 (1st) and 2014 (2nd) and they were offered benefits such as preferential participation in national R&D projects, tax deductions, etc.
The effective period of the status as innovation pharmaceutical company is 3 years from the date of certification.
The Ministry of Health and Welfare announced on the 26th that it had reviewed the 41 pharmaceutical companies, which were designated as innovative pharmaceutical companies in 2012 and recently applied to renew their certification, and 36 of them successfully renewed their status. The 31 companies include 30 general pharmaceutical companies, 5 bio ventures, and 5 foreign pharmaceutical companies.
The specific list of the 36 companies is as follows: Green Cross Corp. [006280], Daewoong Pharm. [069620], Daewon Pharm. [003220], Dongkook Pharm. [086450], Boryung Pharm. [003850], Bukwang Pharm. [003000], Samjin Pharm. [005500], Celltrion Pharm. [068270], Shinpoong Pharm. [019170], Ahngook Pharm. [001540], Yuhan Corp. [000100], Ilyang Pharm. [007570], Chong Kun Dang Pharm[185750], Taejoon Pharm., Korea United Pharm, Handok Pharm [002390], Hanlim Pharm., Hanmi Pharm. [128940], CJ HealthCare, JW THERIAC Pharmaceutical Corp. [001060], LG Life Sciences [068870], SK Chemicals [006120], Kuhnil Pharm., Daehwa Pharm. [067080], Samyang BioPharm., ST Pharm, ISU ABXIS [086890], Kolmar Korea [161890], HanAll BIOPharma [009420], Hyundai Pharm. [004310], Medytox [086900], ViroMed [084990], BC World Pharm [200780], Bioneer [064550], CrystalGenomics, and Korea Otsuka Pham.
The 5 innovative pharmaceutical companies that failed to renew their status this time include Kwang Dong Pharm., Donghwa Pharm., Il-dong Pharm., SK Bio-Pharm., and Binex.
The Ministry of Health and Welfare explained that the sales of the innovative pharmaceutical companies’ every medical product increased and their investments went up as well after they obtained certification (2012-2014) than before (2009-2011). Innovative pharmaceutical companies are the companies that are certified to have excellent and sufficient ability to develop new drugs and enter overseas markets, based on Special Act on Fostering and Support of Pharmaceutical Industry.
The Ministry of Health and Welfare has been enforcing the innovative pharmaceutical certification system since 2012 to promote the growth and international competitiveness of the pharmaceutical industry. The ministry selected a total of 46 innovative pharmaceutical companies through certification in 2012 (1st) and 2014 (2nd) and they were offered benefits such as preferential participation in national R&D projects, tax deductions, etc.
The effective period of the status as innovation pharmaceutical company is 3 years from the date of certification.
